NO20073737L - Hjelp for influensavirus - Google Patents

Hjelp for influensavirus

Info

Publication number
NO20073737L
NO20073737L NO20073737A NO20073737A NO20073737L NO 20073737 L NO20073737 L NO 20073737L NO 20073737 A NO20073737 A NO 20073737A NO 20073737 A NO20073737 A NO 20073737A NO 20073737 L NO20073737 L NO 20073737L
Authority
NO
Norway
Prior art keywords
influenza
cell
nucleic acid
virus
influenza virus
Prior art date
Application number
NO20073737A
Other languages
English (en)
Inventor
Emmie De Wit
Monique Spronken
Ron A M Fouchier
Albert Osterhaus
Original Assignee
Univ Erasmus Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus Medical Ct filed Critical Univ Erasmus Medical Ct
Publication of NO20073737L publication Critical patent/NO20073737L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Oppfinnelsen angår feltet influensavaksineproduksjon. Influensavaksiner er blitt produsert i befruktede hønseegg i over 50 år, men i det senere er det blitt gjort betydelige forsøk på å utvikle cellekultursystemer for vaksineproduksjon. Oppfinnelsen frembringer en nukleinsyre omfattende et influensagensegment og en bakteriofag polymerasepromoter eller en komplementær tråd i nevnte nukleinsyre, og en celle omfattende en slik nukleinsyre som er i stand til å produsere det ønskede influensavirus. Videre frembringer oppfinnelsen en sammensetning omfattende en celle eller materiale avledet fra en celle ifølge oppfinnelsen, og et virus eller materiale avledet fra en viruspartikkel ifølge oppfinnelsen.
NO20073737A 2004-12-24 2007-07-18 Hjelp for influensavirus NO20073737L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078527 2004-12-24
US64100305P 2005-01-04 2005-01-04
PCT/EP2005/057092 WO2006067211A1 (en) 2004-12-24 2005-12-22 Rescue of influenza virus

Publications (1)

Publication Number Publication Date
NO20073737L true NO20073737L (no) 2007-09-21

Family

ID=34928779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073737A NO20073737L (no) 2004-12-24 2007-07-18 Hjelp for influensavirus

Country Status (20)

Country Link
US (2) US7959930B2 (no)
EP (2) EP1831357B1 (no)
JP (2) JP5620048B2 (no)
KR (1) KR101272487B1 (no)
CN (1) CN101379183B (no)
AU (1) AU2005318087B2 (no)
BR (1) BRPI0518568A2 (no)
CA (1) CA2592439C (no)
DK (1) DK1831357T3 (no)
ES (1) ES2395813T3 (no)
HK (1) HK1125674A1 (no)
IL (1) IL183888A (no)
MX (1) MX2007007889A (no)
NO (1) NO20073737L (no)
NZ (1) NZ556061A (no)
PT (1) PT1831357E (no)
RU (2) RU2435855C2 (no)
TW (2) TWI402344B (no)
WO (1) WO2006067211A1 (no)
ZA (1) ZA200705145B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101105984B1 (ko) 2001-01-19 2012-01-18 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
CN1646684B (zh) 2002-02-21 2010-10-06 免疫医疗疫苗公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
BRPI0518568A2 (pt) * 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP1917352A4 (en) 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2377552A3 (en) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
BRPI0707300B8 (pt) 2006-01-27 2021-05-25 Novartis Ag vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
EP2010557B1 (en) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
BRPI0716536A2 (pt) 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US20110014230A1 (en) 2008-03-18 2011-01-20 Novartis Ag preparation of influenza virus vaccine antigens
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
KR20130115105A (ko) * 2010-06-02 2013-10-21 박스터 헬쓰케어 에스에이 Rna 바이러스를 생산하는 방법 및 헬퍼 바이러스
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2014145287A2 (en) * 2013-03-15 2014-09-18 University Of Maryland Swine influenza viruses and constructs and uses thereof
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CA2986701A1 (en) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
KR102576962B1 (ko) 2015-07-07 2023-09-11 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6887699B1 (en) * 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
BRPI0009580B8 (pt) 1999-04-06 2021-05-25 Wisconsin Alumni Res Found processo para preparar vírus influenza infecciosos na ausência de um vírus auxiliar, preparação de vírus influenza infeccioso recombinante, e, composição.
DE122007000061I2 (de) 1999-07-14 2011-07-21 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren.
EP1218499A2 (en) * 1999-08-02 2002-07-03 Wyeth RESCUE OF MUMPS VIRUS FROM cDNA
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
DE60137345D1 (de) 2000-04-28 2009-02-26 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
EP1292614A2 (en) * 2000-06-23 2003-03-19 American Cyanamid Company Nucleotide sequence of influenza a/udorn/72 (h3n2) genome
CN1646684B (zh) * 2002-02-21 2010-10-06 免疫医疗疫苗公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
CN1678345B (zh) * 2002-04-26 2013-09-11 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
BRPI0518568A2 (pt) * 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico

Also Published As

Publication number Publication date
CN101379183B (zh) 2013-07-03
RU2011122117A (ru) 2012-12-10
US20120156241A1 (en) 2012-06-21
US7959930B2 (en) 2011-06-14
TW201235472A (en) 2012-09-01
JP2012147789A (ja) 2012-08-09
CA2592439C (en) 2014-06-03
PT1831357E (pt) 2012-12-17
CN101379183A (zh) 2009-03-04
EP2295542A1 (en) 2011-03-16
NZ556061A (en) 2009-06-26
KR101272487B1 (ko) 2013-06-07
JP5702321B2 (ja) 2015-04-15
TW200636070A (en) 2006-10-16
US20080050401A1 (en) 2008-02-28
ES2395813T3 (es) 2013-02-15
EP2295542B1 (en) 2013-01-30
CA2592439A1 (en) 2006-06-29
KR20070110838A (ko) 2007-11-20
BRPI0518568A2 (pt) 2008-11-25
IL183888A0 (en) 2007-10-31
HK1125674A1 (en) 2009-08-14
JP2008525003A (ja) 2008-07-17
DK1831357T3 (da) 2012-12-10
EP1831357A1 (en) 2007-09-12
MX2007007889A (es) 2008-01-22
TWI402344B (zh) 2013-07-21
JP5620048B2 (ja) 2014-11-05
AU2005318087A1 (en) 2006-06-29
TWI495724B (zh) 2015-08-11
AU2005318087B2 (en) 2011-04-21
EP1831357B1 (en) 2012-10-17
RU2007128336A (ru) 2009-01-27
IL183888A (en) 2013-05-30
RU2435855C2 (ru) 2011-12-10
ZA200705145B (en) 2009-09-30
WO2006067211A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
NO20073737L (no) Hjelp for influensavirus
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
DK1685243T3 (da) Immortaliserede fuglecellelinjer til virusproduktion
WO2005115448A3 (en) Multi plasmid system for the production of influenza virus
WO2006071563A3 (en) Non-tumorigenic mdck cell line for propagating viruses
MX2010003202A (es) Metodo para producir virus de la gripe.
TW200642700A (en) Chemically defined stabiliser
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
BR112012000942B8 (pt) processos para a produção de poliovírus, e para produzir uma vacina contra pólio
EA200970271A1 (ru) Получение вакцин против вируса гриппа без использования куриных эмбрионов
BRPI0516323A (pt) construtos de rna
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
WO2009080806A3 (en) Modified influenza virus
BRPI0911956A2 (pt) mólecula de ácido nucleico isolado, construção de dna, polipeptídeo isolado com atividade pesticida, composição, método para controlar e elimanar uma população de praga de pelidópteros, métodos para produzir um polipetídeo com atividade pesticisa e para proteger a planta contra pragas e variante isolada da seq id no.1
MX2021009554A (es) Produccion de virus en cultivos celulares.
AU2014202470A1 (en) High titer recombinant influenza viruses for vaccines
WO2018097603A3 (ko) 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
PH12020552197A1 (en) Influenza virus hemagglutinin mutants
AR102803A1 (es) Vacunas de reovirus aviar
JP2016086711A5 (no)
UA100849C2 (ru) Способ репликации вируса гриппа в культуре
Roedig et al. Impact of different influenza cultivation conditions on HA N-Glycosylation
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse
WO2008136253A1 (ja) ウイルスベクターおよびその利用

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ERASMUS UNIVERSITY MEDICAL CENTER, NL

Owner name: ABBOTT BIOLOGICALS BV, NL

FC2A Withdrawal, rejection or dismissal of laid open patent application